News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
Subscribe To Our Newsletter & Stay Updated
